In a reversal of the medicines cost-effectiveness watchdog for England and Wales’ initial Appraisal Consultation Document, the National Institute for Health and Care Excellence (NICE) has today issued its final decision regarding the blood cancer drug Gazyvaro (obinutuzumab).
It recommends that Gazyvaro, from Swiss pharma giant Roche (ROG: SIX), is made routinely available in combination with chemotherapy followed by obinutuzumab maintenance for the treatment of patients with previously untreated advanced follicular lymphoma (FL) who are at higher risk of relapse (patients with a Follicular Lymphoma Prognostic Index (FLIPI) score of 2 or more).
The list price of the drug is £3,312 ($4,574) per 1,000mg vial (excluding VAT; British national formulary [BNF] online, August 2017).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze